NASDAQ:PLRX

Pliant Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PLRX

*Your capital is at risk

$1.18

+0.0200 (+1.72%)

At Close: Jun 03, 2026

Pliant Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -61.41. In total, the insiders bought 8.23M and sold 3.23M PLRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-61.41
● Buy	8.23M shares
● Sell	3.23M shares
70% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Apr 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -61.41. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 10, 2025 Buy	Common Stock	Kuo Minnie Chief Operating Officer	C-Suite Officer	0 Value: $0
Dec 10, 2025 Buy	Stock Option (Right to Buy)	Kuo Minnie Chief Operating Officer	C-Suite Officer	55 200 Value: $614.9K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Bruhn Suzanne Louise Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Knobil Katharine Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Mccourt Thomas A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Curnutte John T Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Krognes Steve E. Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Cline Darren S Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Pyott David E I Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Huh Hoyoung Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Crowell Gayle A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Crowell Gayle A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Huh Hoyoung Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Pyott David E I Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Cline Darren S Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Krognes Steve E. Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Curnutte John T Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Mccourt Thomas A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Knobil Katharine Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Bruhn Suzanne Louise Director	Director	30 000 Value: $48.3K
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Cheung Lily Chief Human Resource Officer	Officer	51 750 Value: $576.5K
Jan 23, 2025 Buy	Common Stock A-Award	Cheung Lily Chief Human Resource Officer	Officer	25 875 Value: $288.2K
Jan 23, 2025 Buy	Common Stock A-Award	Ouimette Mike General Counsel & Corp. Sec'y	Officer	35 000 Value: $389.9K
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Ouimette Mike General Counsel & Corp. Sec'y	Officer	70 000 Value: $779.8K
Jan 23, 2025 Buy	Common Stock A-Award	Hull Hans Chief Business Officer	Officer	40 150 Value: $447.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PLIANT THERAPEUTICS INC.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which complet...

Read Full Profile Here